E. Kaminskas

发表

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Richard Pazdur, Robert Justice, Nitin Mehrotra, 2015, Clinical Cancer Research.

Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes

R. Pazdur, Atiqur Rahman, A. Farrell, 2005, Clinical Cancer Research.

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

Richard Pazdur, Rajeshwari Sridhara, R. Pazdur, 2005, The oncologist.

Accumulation of DNA strand breaks and methotrexate cytotoxicity.

E. Kaminskas, J. Li, 1984, Proceedings of the National Academy of Sciences of the United States of America.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Pazdur, A. Al-Hakim, R. Justice, 2015, Clinical Cancer Research.

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

C. Garnett, L. Burke, R. Pazdur, 2012, Clinical Cancer Research.

Urocanase and N-formimino-L-glutamate formiminohydrolase of Bacillus subtilis, two enzymes of the histidine degradation pathway.

B. Magasanik, E. Kaminskas, Y. Kimhi, 1970, The Journal of biological chemistry.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Pazdur, A. Khandelwal, F. Borrego, 2012, Clinical Cancer Research.

NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.

Jonathan H Seltzer, P. Sager, J. Reiffel, 2016, American heart journal.

Novel oral anticoagulants and reversal agents: Considerations for clinical development.

Jonathan H Seltzer, D. Singer, P. Kowey, 2015, American heart journal.

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation

K. Goldberg, Amy McKee, R. Pazdur, 2018, The oncologist.

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

R. Pazdur, V. Goodman, J. Gobburu, 2008, Clinical Cancer Research.

O6-methylguanine-DNA methyltransferase in lymphocytes of the elderly with and without Alzheimer's disease.

R. Setlow, E. Kaminskas, L. G. Wang, 1989, Mutation research.

Deficient repair of DNA lesions in Alzheimer's disease fibroblasts.

E. Kaminskas, J. Li, James Li, 1985, Biochemical and biophysical research communications.

Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies Report from the Fda

R. Pazdur, R. Lechleider, R. Justice, 2022 .

Inactivation of protein synthesis stimulating activity in serum by cells

E. Kaminskas, 1973, Journal of cellular physiology.

The pH-dependence of sugar-transport and glycolysis in cultured Ehrlich ascites-tumour cells.

E. Kaminskas, 1978, The Biochemical journal.

DNA fragmentation in permeabilized cells and nuclei. The role of (Ca2+ + Mg2+)-dependent endodeoxyribonuclease.

E. Kaminskas, J. Li, 1989, The Biochemical journal.

Inhibition of sugar uptake by methotrexate in cultured Ehrlich ascites carcinoma cells.

E. Kaminskas, 1979, Cancer research.

Inhibitionof Sugar Uptakeby Methotrexatein CulturedEhrlich AscitesCarcinomaCells1

E. Kaminskas, 1978 .

Sequential synthesis of histidine-degrading enzymes in Bacillus subtilis.

B. Magasanik, E. Kaminskas, 1970, The Journal of biological chemistry.

Progressive formation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea.

E. Kaminskas, J. Li, 1987, Cancer research.

Experimental Pyelonephritis. VII. Evidence on the Mechanisms by Which Obstruction of Urine Flow Enhances Susceptibility to Pyelonephritis ‡

P. Beeson, E. Kaminskas, L. R. Freedman, 1960, The Yale journal of biology and medicine.

Effects of methotrexate and of environmental factors on glycolysis and metabolic energy state in cultured Ehrlich ascites carcinoma cells.

E. Kaminskas, A. Nussey, 1978, Cancer research.

Cyclic amp and growth of ehrlich ascites tumor cells. Lack of cyclic amp elevation in nutritionally deprived cells and mechanism of retardation of growth by dibutyryl cyclic amp.

E. Henshaw, E. Kaminskas, M. Field, 1976 .

FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

Lei Nie, Dhananjay D. Marathe, Richard Pazdur, 2015, Clinical Cancer Research.

U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.

R. Pazdur, M. Rothmann, C. Ko, 2014, The oncologist.

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

R. Pazdur, R. Justice, C. Ko, 2014, Clinical Cancer Research.

Cell-serum factor interaction. Characteristics of stimulation of protein synthesis in Ehrlich ascites cells by factors in serum and in cell extracts.

E. Kaminskas, 1975, Experimental cell research.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

Managing Institutional Long-Term Care for the Elderly

E. Kaminskas, J. Kasten, M. I. May, 1991 .

DNA fragmentation in permeabilized cells.

E. Kaminskas, J. Li, 1987, The Biochemical journal.

Repair of DNA damage induced by oxygen radicals in human non-proliferating and proliferating lymphocytes.

E. Kaminskas, J. Li, 1992, Mutation research.

Changes in adenylate energy charge in Ehrlich ascites tumor cells deprived of serum, glucose, or amino acids.

E. Kaminskas, T. R. Live, 1975, The Journal of biological chemistry.

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

K. Goldberg, R. Pazdur, C. Ko, 2017, Clinical Cancer Research.

Serum-mediated stimulation of protein synthesis in Ehrlich ascites tumor cells.

E. Kaminskas, 1972, The Journal of biological chemistry.

Ribonucleotide depletion in glucose-deprived tumor cells - the role of RNA synthesis.

E. Kaminskas, E Kaminskas, 1979, Biochemical and biophysical research communications.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

R. Pazdur, V. Goodman, J. Gobburu, 2008, Clinical Cancer Research.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Pazdur, A. Khandelwal, F. Borrego, 2012, Clinical Cancer Research.

Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies

R. Pazdur, R. Lechleider, R. Justice, 2008, Clinical Cancer Research.

[148] Histidine degradation (Bacillus subtilis)

B. Magasanik, E. Kaminskas, Y. Kimhi, 1971 .

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

Gemtuzumab ozogamicin.

R. Pazdur, A. Farrell, R. Kane, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.